Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

295,882 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC-1.
Cai Z, Xia Z, He AL, Dong YJ, Wang Y, Liao A, Song Y, Song Mm J, Uhlar C, Chastain K, Watkins L, Luo X, Huang L, Niu Z, Quijano Cardé NA, Guo Y, Xu H, Verona RI, Zhou L, Li J, Fu W, Niu T, Du J. Cai Z, et al. Among authors: wang y. Cancer. 2024 Dec 11. doi: 10.1002/cncr.35665. Online ahead of print. Cancer. 2024. PMID: 39660861
Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.
Fu W, Bang SM, Huang H, Kim K, Li W, An G, Lee JJ, Cai Z, Jin J, Wang Y, Lin TL, Chim CS, Qi M, Wang J, Lu X, Song Y, Jia B, Yang X, Liu W, Zhou T, Yin L, Li Y, Zhang R, Hou J, Wang J. Fu W, et al. Among authors: wang j, wang y. Clin Lymphoma Myeloma Leuk. 2023 Jun;23(6):446-455.e4. doi: 10.1016/j.clml.2023.02.009. Epub 2023 Mar 4. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37024420 Free article. Clinical Trial.
Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial.
Zhou H, Wang Y, Chen J, He A, Jin J, Lu Q, Zhao Y, Li J, Hou M, Su L, Lai X, Wang W, Liu L, Ma Y, Gao D, Lai W, Zhou X, Jing H, Zhang J, Yang W, Ran X, Lin C, Hao J, Xiao T, Huang Z, Zhu Z, Wang Q, Fang B, Wang B, Song Y, Cai Z, Liu B, Zhu Y, Yang X, Kang X, Li J, Chen W. Zhou H, et al. Among authors: wang w, wang y, wang b, wang q. Ann Hematol. 2024 Mar;103(3):855-868. doi: 10.1007/s00277-023-05558-y. Epub 2023 Dec 19. Ann Hematol. 2024. PMID: 38112795 Free PMC article.
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.
Fu W, Bang SM, Huang H, Kim K, Li W, An G, Lee JJ, Cai Z, Jin J, Wang Y, Chim CS, Carson R, Liu R, Zhao M, Chen X, Cui C, Hou J, Wang J. Fu W, et al. Among authors: wang j, wang y. Ann Hematol. 2024 Sep 4. doi: 10.1007/s00277-024-05958-8. Online ahead of print. Ann Hematol. 2024. PMID: 39227450
Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China.
Gao Y, Liu Y, Wang Y, Zhang Q, Wu D, Ye X, Wu J, Xu W, Zhou J, Yang Y, Cen H, Zhang F, Xiang Y, Tang X, Ding K, Lin J, Ma L, Wang S, Yu H, Zhao Y, Song B, Lv F, Huang H. Gao Y, et al. Among authors: wang y, wang s. Cancer. 2023 Feb 15;129(4):551-559. doi: 10.1002/cncr.34544. Epub 2022 Dec 21. Cancer. 2023. PMID: 36541221 Free article.
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W, Tong S, Hu B, Wan T, Tang H, Zhao F, Jiao T, Li J, Zhang Z, Cai J, Ye H, Wang Z, Chen S, Wang Y, Li X, Wang F, Cao J, Tian L, Zhao X, Chen M, Wang H, Cai S, Hu M, Bai Y, Lu S. Zhang W, et al. Among authors: wang h, wang f, wang z, wang y. J Immunother Cancer. 2023 Sep;11(9):e007366. doi: 10.1136/jitc-2023-007366. J Immunother Cancer. 2023. PMID: 37730273 Free PMC article. Clinical Trial.
295,882 results
You have reached the last available page of results. Please see the User Guide for more information.